Expression of LKB1 tumor suppressor in non-small cell lung cancer determines sensitivity to 2-deoxyglucose

Journal of Thoracic and Cardiovascular Surgery

Volumn 137, Issue 3, 2009, Pages 580-586

  Inge, Landon J ^a   Coon, Keith D ^a   Smith, Michael A ^a   Bremner, Ross M ^a  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; DRUG VEHICLE; PROTEIN KINASE LKB1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL METABOLISM; CELL VIABILITY; CONTROLLED STUDY; DISEASE MARKER; DRUG SENSITIVITY; DRUG TARGETING; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYGLUCOSE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 60949083610     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.11.029     Document Type: Article

References (23)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Sharma S.V., Bell D.W., Settleman J., and Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev 7 (2007) 169-181
3. Alessi D.R., Sakamoto K., and Bayascas J.R. LKB1-dependent signaling pathways. Ann Rev Biochem 75 (2006) 137-163
4. Matsumoto S., Iwakawa R., Takahashi K., Kohno T., Nakanishi Y., Matsuno Y., et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 26 (2007) 5911-5918
5. Sanchez-Cespedes M., Parrella P., Esteller M., Nomoto S., Trink B., Engles J.M., et al. Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62 (2002) 3659-3662
6. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature. 200716;448:807-10.
7. Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene 26 (2007) 7825-7832
8. Shah U., Sharpless N.E., and Hayes D.N. LKB1 and lung cancer: more than the usual suspects. Cancer Res 68 (2008) 3562-3565
9. Shaw R.J. Glucose metabolism and cancer. Current Opin Cell Biol 18 (2006) 598-608
10. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 (2003) 577-590
11. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
12. Corradetti M.N., Inoki K., Bardeesy N., DePinho R.A., and Guan K.L. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18 (2004) 1533-1538
13. Carretero J., Medina P.P., Blanco R., Smit L., Tang M., Roncador G., et al. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 26 (2007) 1616-1625
14. Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6 (2004) 91-99
15. Karczmar G.S., Arbeit J.M., Toy B.J., Speder A., and Weiner M.W. Selective depletion of tumor ATP by 2-deoxyglucose and insulin, detected by 31P magnetic resonance spectroscopy. Cancer Res 52 (1992) 71-76
16. Maschek G., Savaraj N., Priebe W., Braunschweiger P., Hamilton K., Tidmarsh G.F., et al. 2-Deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64 (2004) 31-34
17. Simons A.L., Ahmad I.M., Mattson D.M., Dornfeld K.J., and Spitz D.R. 2-Deoxy-d-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res 67 (2007) 3364-3370
18. Garriga-Canut M., Schoenike B., Qazi R., Bergendahl K., Daley T.J., Pfender R.M., et al. 2-Deoxy-d-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat Neurosci 9 (2006) 1382-1387
19. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K.D., Danenberg P.V., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17 (2006) 1818-1825
20. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
21. Lum J.J., DeBerardinis R.J., and Thompson C.B. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol 6 (2005) 439-448
22. Reggiori F., and Klionsky D.J. Autophagosomes: biogenesis from scratch?. Curr Opin Cell Biol 17 (2005) 415-422
23. Liang J., Shao S.H., Xu Z.X., Hennessy B., Ding Z., Larrea M., et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 9 (2007) 218-224